Related news from |
Thu, 28 Mar 2024 15:30:42 +0000 |
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
|
Tue, 26 Mar 2024 22:15:18 +0000 |
Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $68.64, indicating a -0.88% shift from the previous trading day.
|
Thu, 21 Mar 2024 13:00:11 +0000 |
Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock
Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
|
Wed, 20 Mar 2024 22:00:19 +0000 |
Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $73.11, indicating a +1.25% shift from the previous trading day.
|
Tue, 19 Mar 2024 13:30:09 +0000 |
Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?
According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
|
Thu, 14 Mar 2024 22:00:19 +0000 |
Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors
Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.
|
Fri, 08 Mar 2024 23:00:12 +0000 |
Ligand Pharmaceuticals (LGND) Gains As Market Dips: What You Should Know
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.77, marking a +1.79% move from the previous day.
|
Thu, 07 Mar 2024 14:00:10 +0000 |
Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now?
Ligand (LGND) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
|
Tue, 05 Mar 2024 21:01:00 +0000 |
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
SAN DIEGO, March 05, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.
|
Mon, 04 Mar 2024 13:00:00 +0000 |
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 04, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024.
|
Thu, 29 Feb 2024 14:30:10 +0000 |
Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest?
According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
|
Wed, 28 Feb 2024 14:38:29 +0000 |
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript February 27, 2024 Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58. LGND isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Korenberg – COO: Operator: Ladies and gentlemen, […]
|
Wed, 28 Feb 2024 12:34:00 +0000 |
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.
|
Wed, 28 Feb 2024 10:59:00 +0000 |
Ligand Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Ligand Pharmaceuticals ( NASDAQ:LGND ) Full Year 2023 Results Key Financial Results Revenue: US$131.3m (down 33% from...
|
Wed, 28 Feb 2024 03:15:09 +0000 |
Q4 2023 Ligand Pharmaceuticals Inc Earnings Call
Q4 2023 Ligand Pharmaceuticals Inc Earnings Call
|
Tue, 27 Feb 2024 12:52:10 +0000 |
Ligand Pharmaceuticals Inc (LGND) Reports Solid Earnings Amidst Operational Transformation
Q4 and Full Year 2023 Financials Show Growth and Strategic Refocus
|
Tue, 27 Feb 2024 12:00:00 +0000 |
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, February 27, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.
|
Thu, 22 Feb 2024 21:01:00 +0000 |
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
SAN DIEGO, February 22, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol®, a Ligand technology.
|
Tue, 20 Feb 2024 23:00:17 +0000 |
Why Ligand Pharmaceuticals (LGND) Dipped More Than Broader Market Today
Ligand Pharmaceuticals (LGND) reachead $72.37 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.
|
Fri, 16 Feb 2024 13:00:00 +0000 |
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
SAN DIEGO, February 16, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments. Both executives will report to CEO Todd Davis.
|